Hutchmed Launches Global Trial of HMPL-A580 in Patients With Solid Tumors

MT Newswires Live

03/04

Hutchmed (HCM) said Wednesday it has started a phase I/IIa clinical trial of its HMPL-A580 antibody-targeted therapy conjugate candidate in certain cancer patients in the US and China.

The trial covers patients with unresectable, advanced or metastatic solid tumors.

In phase I, patients will receive HMPL-A580 intravenously at predefined dose levels to help determine the maximum tolerated dose and recommended dose for expansion.

Phase IIa will help further characterize the candidate's safety, tolerability and preliminary anti-tumor activity in selected solid tumors, and determine the recommended dose for the next phase, the company said.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2616390515"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616390515\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616390515?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 18:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616390515","market":"us","top_or_hot":-1,"title":"Hutchmed Launches Global Trial of HMPL-A580 in Patients With Solid Tumors","media":"MT Newswires Live","content":"<html><body><p> Hutchmed (HCM) said Wednesday it has started a phase I/IIa clinical trial of its HMPL-A580 antibody-targeted therapy conjugate candidate in certain cancer patients in the US and China.</p><p>The trial covers patients with unresectable, advanced or metastatic solid tumors.</p><p>In phase I, patients will receive HMPL-A580 intravenously at predefined dose levels to help determine the maximum tolerated dose and recommended dose for expansion.</p><p>Phase IIa will help further characterize the candidate's safety, tolerability and preliminary anti-tumor activity in selected solid tumors, and determine the recommended dose for the next phase, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hutchmed Launches Global Trial of HMPL-A580 in Patients With Solid Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHutchmed Launches Global Trial of HMPL-A580 in Patients With Solid Tumors\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-03-04 18:50</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Hutchmed (HCM) said Wednesday it has started a phase I/IIa clinical trial of its HMPL-A580 antibody-targeted therapy conjugate candidate in certain cancer patients in the US and China.</p><p>The trial covers patients with unresectable, advanced or metastatic solid tumors.</p><p>In phase I, patients will receive HMPL-A580 intravenously at predefined dose levels to help determine the maximum tolerated dose and recommended dose for expansion.</p><p>Phase IIa will help further characterize the candidate's safety, tolerability and preliminary anti-tumor activity in selected solid tumors, and determine the recommended dose for the next phase, the company said.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2616390515","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616390515","pubTimestamp":1772621438,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hutchmed  said Wednesday it has started a phase I/IIa clinical trial of its HMPL-A580 antibody-targeted therapy conjugate candidate in certain cancer patients in the US and China.The trial covers patients with unresectable, advanced or metastatic solid tumors.In phase I, patients will receive HMPL-A580 intravenously at predefined dose levels to help determine the maximum tolerated dose and recommended dose for expansion.Phase IIa will help further characterize the candidate's safety, tolerability and preliminary anti-tumor activity in selected solid tumors, and determine the recommended dose for the next phase, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4531":"中概回港概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","HCM":"和黄医药"},"translate_title":"和黄医药启动HMPL-A580在实体瘤患者中的全球试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCM":1},"content_text":"Hutchmed (HCM) said Wednesday it has started a phase I/IIa clinical trial of its HMPL-A580 antibody-targeted therapy conjugate candidate in certain cancer patients in the US and China.The trial covers patients with unresectable, advanced or metastatic solid tumors.In phase I, patients will receive HMPL-A580 intravenously at predefined dose levels to help determine the maximum tolerated dose and recommended dose for expansion.Phase IIa will help further characterize the candidate's safety, tolerability and preliminary anti-tumor activity in selected solid tumors, and determine the recommended dose for the next phase, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}